FDA Approves Sanofi’s Infilbray for Type 3 Gaucher Disease

The FDA approved Sanofi’s Infilbray (venglustat) to treat neurological manifestations of type 3 Gaucher disease in adults and children weighing at least 15 kg. It is the first medicine approved in the U.S. specifically for neurological symptoms of this form of Gaucher disease, a rare inherited disorder that can impair cognition, coordination and balance.

The approval was based on LEAP2MONO, a Phase 3 trial that randomized 43 patients aged 12 and older whose systemic symptoms had stabilized after at least three years of enzyme replacement therapy. The study compared once-daily oral Infilbray with intravenous imiglucerase, an enzyme replacement therapy given every two weeks.

At 52 weeks, Infilbray showed statistically significant superiority over imiglucerase on a combined test of changes in motor and cognitive function (p = 0.0137). Infilbray inhibits glucosylceramide synthase and is designed to cross the blood-brain barrier to address the accumulation of glycosphingolipids implicated in the disease.

The prescribing information includes warnings for suicidal ideation and behavior, lens opacification in pediatric patients and embryo-fetal toxicity. Diarrhea, spleen enlargement and nausea each occurred in 14% of patients receiving Infilbray, compared with 0%, 0% and 5%, respectively, among those receiving imiglucerase.

The open-label phase of LEAP2MONO is ongoing, and Sanofi plans to report those results when available. Infilbray remains under regulatory review for type 3 Gaucher disease in the European Union, Japan and other jurisdictions, with additional submissions planned for 2026 and 2027.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!

Sign up now!

  • <<
  • >>

Join the Discussion